|
Video: What is a Stock Split?
|
|
SQZ Biotechnologies is a biotechnology company developing cell therapies for patients with cancer and other serious conditions. In oncology, Co. is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Co.'s product candidate pipeline includes: SQZ® Enhanced Antigen Presenting Cell Platform, which is designed to generate tumor-specific CD8+ T cell activation to drive the antitumor immune response; and SQZ® Activating Antigen Carrier Platform, which is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells with tumor-specific antigens and adjuvant. According to our SQZ split history records, SQZ Biotechnologies has had 0 splits. | |
|
SQZ Biotechnologies (SQZ) has 0 splits in our SQZ split history database.
Looking at the SQZ split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SQZ Biotechnologies shares, starting with a $10,000 purchase of SQZ, presented on a split-history-adjusted basis factoring in the complete SQZ split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/02/2020 |
|
End date: |
07/03/2023 |
|
Start price/share: |
$14.50 |
|
End price/share: |
$0.43 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.00% |
|
Average Annual Total Return: |
-73.20% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$300.00 |
|
Years: |
2.66 |
|
|
|
|
|